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Investigate degradantAbstract A sensitive stability indicating high-performance thin-layer chromatographic method
was developed and validated for quantitative determination of Acyclovir in tablets. Chromato-
graphic separation was performed on a precoated silica gel 60F254 HPTLC plates using Toluene:
n-Butanol: Methanol: Water (5.0:3.0:1.0:1.0 v/v/v/v) as a mobile phase. A TLC scanner set at
259 nm was used for direct evaluation of the chromatograms in reﬂectance/absorbance mode. Acy-
clovir and degradant were satisfactorily resolved with Rf values of 0.62 ± 0.05, 0.78 ± 0.05, respec-
tively. Calibration curve was a polynomial in the concentration range of 200–1000 ng/band. The
high correlation coefﬁcient (r2 > 0.9991) values indicated clear correlations between the investi-
gated compound concentrations and their peak areas within the test ranges. The method was val-
idated according to ICH guidelines. The repeatability and intermediate precision, expressed by the
RSD, were less than 2.0%. The accuracy and validity of the method were further ascertained by
performing recovery studies via a standard addition method. The accuracy of the method expressed
as percent recovery was satisfactory (99.85%). The drug was subjected to the International Confer-
ence on Harmonization (ICH)-prescribed hydrolytic, oxidative, photolytic and thermal stress con-
ditions. The method was validated according to ICH guidelines. The drug showed instability in
alkaline and oxide while it remained stable in heat and UV radiation conditions. The proposed
HPTLC method was utilized to investigate the alkaline degradation of Acyclovir (ACY). The per-
formance of the method was validated according to the present ICH guidelines for speciﬁcity, limit
of detection, limit of quantiﬁcation, linearity, accuracy, precision, ruggedness and robustness.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Acyclovir (Fig. 1) (9-[(2-hydroxyethoxy) methyl] guanine,
zovirax) is a guanosine analogue with acyclic side chain at
Figure 1 Structure of Acyclovir.
246 P.M. Patil et al.the 9 position. It is used orally for the treatment and prophy-
laxis of initials and recurrent episodes of genital and labial her-
pes and for the treatment of herpes zoster and varicella
(chickenpox) in immunocompetent individuals.1–3 The chemi-
cal name for acyclovir is 2-amino-1,9-dihydro-9- [(2-hydroxy-
ethoxy) methyl]-6H-purine-6-one or 9- [(2-hydroxyethoxy)
methyl]-guanine. Its molecular formula is C8H11N5O3, and
molecular weight 225.21 g/mol.4 It is commonly used in the
free acid form in solid oral dosage forms, whereas the sodium
salt is used in parenteral dosage forms.5,6
This drug is an effective agent in the treatment of herpes
virus infections andmay also be used in the prophylaxis of infec-
tions in immune compromised patients. As acyclovir is structur-
ally similar to endogenous substances, its analysis in human
serum is complicated and requires selective analytical methods.
Immunological techniques and HPLC are commonly used
methods for the determination of acyclovir in biological sam-
ples. Acyclovir is a nucleoside analogue with antiviral activity
against herpes viruses. Some HPLC methods for the analysis
of acyclovir in plasma, serum or urine have been published.7,8
However, these analytical methods require the use of an ion
pairing agent,9 column thermostating and ﬂuorimetric detec-
tion10 and also are limited by the lack of sensitivity.
The literature survey also revealed that HPLC methods
have been reported for the estimation of Acyclovir in pharma-
ceutical formulations.11 These methods are developed to elute
the degradation products from the drug. HPLC assay method
was developed and validated for the quantitative determina-
tion of Acyclovir in bulk drugs.12 An isocratic reversed-phase
HPLC method with Photodiode Array detector has been
developed for the assay and purity evaluation of acyclovir
and valacyclovir in bulk drug.13
The limiting factor in the HPLC method is the size of the
column packing. High pressure will be required for sampling
through columns and previously unneeded apparatus will also
required to maintain reproducibility of results in this new
instruments. The advantage of high performance thin layer
chromatography is that a large number of samples can be
simultaneously analysed in a shorter time period. Unlike
HPLC, this method utilizes less quantity of solvents, thus low-
ering the cost of analysis. An ideal stability indicating chro-
matographic method should estimate the drug and also be
able to resolve the drug from its degradation products hence
an attempt has been made to develop an accurate, rapid, spe-
ciﬁc and reproducible method for the determination of acyclo-
vir (ACY) in the presence of their degradation products for the
content analysis during stability studies from pharmaceutical
dosage forms.
HPTLC, because of its speed and sensitivity, has gained con-
siderable attention in recent years for pharmaceutical analysis.According to our research, there is no stability-indicating
HPTLC method reported in the literature that can conduct an
accurate and quantiﬁable analysis of ACY in dosage forms. It
is, therefore, necessary to develop a new stability-indicating
method for the determination and quantitative estimation of
ACY from bulk and pharmaceutical dosage forms.
Nowadays, investigation on the chemical stability and
kinetics of decomposition of drugs is an essential matter to
the quality control of pharmaceuticals and to understand the
degradation pathway of drugs which is important to evaluate
the product’s shelf-life period. There are no earlier reports in
the literature involving stability study on acyclovir by HPTLC.
In the present study an attempt has been made to investigate
the alkaline degradation process of the cited drug using the
proposed HPTLC method.
Hence, the aim of the present work was to develop simple
and sensitive stability-indicating HPTLC method for the quan-
titative determination of acyclovir in pharmaceutical formula-
tions in the presence of its alkaline degradation product.2. Experimental
2.1. Materials and reagents
Acyclovir pure drug (Purity – 99.8%) was procured from
Lupin Limited, Pune (India) as a gift sample. The solvents
methanol, n-butanol, and toluene used were of analytical
reagent grade (Make S.D. Fine chemicals) and procured from
local vendor.
Toluene: n-Butanol: Methanol: Water from S.D. Fine
chemicals, Mumbai Reference standard Acyclovir was pro-
cured from Lupin Ltd. India (purity 99.8) for the gift sample.
2.2. Instrumentation
Microsyringe (Linomat syringe, Hamilton-Bonaduz schweiz,
Camag, Switzerland), pre-coated silica gel 60 F-254 glass
plates (10 · 10 cm with 200 lm thickness HPTLC; Merck,
Germany), linomat 5 automatic sample applicator (Camag,
Muttenz, Switzerland), twin trough chamber 10 · 10 cm
(Camag, Muttenz, Switzerland), UV chamber (Camag, Mut-
tenz, Switzerland), TLC scanner III (Camag, Muttenz, Swit-
zerland), and win CATS version 1.4.0 software (Camag,
Muttenz, Switzerland) were used in this study. Microsoft excel
was also used to treat data statistically.
2.3. Preparation of solution
2.3.1. Standard solution of ACY
Accurately weighed quantity (100 mg) of Acyclovir was trans-
ferred to a 100.0 mL volumetric ﬂask, dissolved and diluted up
to the mark with methanol. From this solution, 5.0 mL was
transferred to a 50.0 mL volumetric ﬂask and diluted to the
mark with methanol (concentration 100 lg/mL). The solution
was mixed and ﬁltered through a 0.2 l membrane ﬁlter.
2.3.2. Laboratory preparation of alkaline degradation product
Aliquot portions (1–9 mL) of the intact ACY working solution
(100 lg/mL) were accurately transferred into a series of 10-mL
measuring ﬂasks. Different portions of the alkaline degrada-
Validated stability indicating HPTLC method for estimation of acyclovir in tablets 247tion product (100 lg/mL) were also added to prepare different
mixtures containing 10–90% of the degradant, and then the
volume was completed with methanol. The samples were ana-
lysed by the proposed HPTLC methods and the concentra-
tions of the intact drug were calculated from the
corresponding regression equations.Figure 2 Scheme of Alkalin
Figure 3 Spectrum of ACY standard and
Figure 4 Typical Den2.3.3. Stock solution of degradant
Accurately weighed quantity (25 mL) of degradant was trans-
ferred to a 25.0 mL volumetric ﬂask, dissolved and diluted
up to the mark with methanol. From this solution, 5.0 mL
was transferred to a 50.0 mL volumetric ﬂask and diluted
to the mark with methanol (concentration 100 lg/mL). Thee Degradation of ACY.
sample measured from 200 to 400nm.
sitogram of ACY.
248 P.M. Patil et al.solution was mixed and ﬁltered through a 0.2 l membrane
ﬁlter.
2.3.4. Sample solution for assay of ACY tablets
Twenty tablets were weighed and ﬁnely powdered. Accurately
weighed quantity of tablet powder equivalent to about 50 mg
of ACY was transferred to a 50.0 mL volumetric ﬂask, added
30 mL methanol and the contents of the ﬂask were sonicated
for about 15 min, volume was then made up to the mark with
methanol. The solution was mixed and ﬁltered through the
Whatman ﬁlter paper no. 41. An aliquot of 1.0 mL of this solu-
tion was diluted to 10.0 mL with methanol yielding 100 lg/mL
solution. The resulting solution was analysed by HPTLC.Table 1 Results of Cochran’s C test.
Concentration
(ng/band)
S.D. Square of S.D.a Sum of
square of S.D
C b
200 295.10 87084.01 1529937.54 0.545
400 432.87 187376.43
500 685.96 470534.26
600 885.97 784942.84
a S.D.: standard deviation of three replicates.
b C: Cochran’s C.
Figure 5 Standard Calibr
Table 2 Results of accuracy studies.
Level of recovery (%) Weight of Tab taken (mg) Amount of dr
ACY
80 100 80
100 80
100 80
100 100 100
100 100
100 100
120 100 120
100 120
100 1202.3.5. Preparation of extensive alkaline induced degradation
product
Accurately weighed 100 mg of ACY was dissolved in 25 mL
methanol. Subsequently, 25 mL of 1 M sodium hydroxide
was added and the solution was heated in a temperature con-
trolled oven at 50 C for 12 h. The solution was concentrated
nearly to dryness under vacuum, cooled to room temperature
(25 C), then quantitatively transferred into a 100-mL measur-
ing ﬂask and neutralized the solution using 1 N HCL and the
volume was completed with methanol. Complete alkaline deg-
radation of the studied drug was conﬁrmed by the proposed
HPTLC method, where no peaks corresponding to intact drug
were detected in case of the degraded samples and the concen-
trations of the intact drug were calculated from the corre-
sponding regression equations as shown in Fig. 2
2.4. Chromatographic conditions
The samples were applied on the plate in the form of band with
band length of 8 mm. The mobile phase consisted of Toluene:
n-butanol: Methanol: Water (5.0:3.0:1.0:1.0 v/v/v/v) and
10 mL of the mobile phase was used in each chromatographic
run. Ascending development technique was carried out in a
twin trough chamber saturated with mobile phase vapours
for 25 min at room temperature (25 ± 2 C). The mobile phaseation Curve for ACY.
ug added (mg) Amount of drug recovered (mg) % recovery
ACY ACY
79.70 99.60
80.02 100.02
80.15 100.27
99.07 99.18
99.54 99.67
100.32 100.23
119.18 99.14
120.11 100.14
120.13 100.18
Table 4 Result of precision and LOD and LOQ data.
Drug % meana S. D. C. V.
Intra-day precision data
ACY 98.15 ±0.4598 0.3228
Inter-day precision data
ACY 99.05 ±0.4310 0.3168
Parameter ACY
LOD and LOQ
Limit of detection (ng/band) 08.08
Limit of quantiﬁcation (ng/band) 12.16
a Average of six determinations.
Table 5 Robustness testing for the HPTLC method.
Factor Chromatographic changes
Level Peak area Rf value
Mobile phase composition (±0.1 ml)
4.9:2.9:0.5:0.5 0.1 14935.32 0.61
5.0+3.0+1.0+1.0 0 15459.56 0.62
5.1:3.1:1.5:1.5 +0.1 15477.50 0.65
RSD 1.65
Amount of mobile phase (v/v) (±1 ml)
9 0.1 15230.50 0.60
10 0 15500.70 0.62
11 +0.1 15429.56 0.67
RSD 1.45
Duration of chamber saturation (±20%)
12 min 20% 15156.80 0.57
15 min 0 15347.16 0.62
18 min +20% 15359.36 0.68
RSD 1.25
Time from spotting to development
5 min – 15322.40 0.55
20 min – 15579.21 0.62
40 min – 15459.46 0.71
RSD 1.35
Time from development to scanning
5 min – 15585.50 0.61
20 min – 15570.56 0.62
40 min – 15455.56 0.73
RSD 1.64
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The bands were scanned using the TLC scanner 3 in the reﬂec-
tance/absorbance mode at 259 nm and all measurements were
operated by the win CATS software. Concentrations of the
sample were determined from the intensity of reﬂected light
and by comparing peak area of sample band with that of the
standard band (see ﬁg. 3).
2.5. Method validation
The proposed HPTLC method was validated according to
ICH guidelines (ICH 1994, 1996). The following parameters
were used for validation of the developed method.
2.5.1. Linearity
Linear relationship between peak area and concentration of
the drugs was evaluated over a range of concentrations
expressed in ng/band, making ﬁve measurements at 10 concen-
tration levels in the range of 100 ng/band – 600 ng/band.
2.5.2. Accuracy
Recovery studies were carried out by spiking three different
known amounts of pure drug (at 80%, 100% and 120% of
label claim) to the pre-analysed tablet powder (standard addi-
tion method). Hence, 100, 200, and 400 mg of acyclovir were
spiked to the pre-analysed tablet powder containing 200 mg
of acyclovir.
2.5.3. Precision
The precision of the method was veriﬁed by repeatability and
intermediate precision studies. Repeatability studies were per-
formed by analysing the tablet sample six times at 100% of test
concentration on the same day. The intermediate precision of
the method was checked by repeating the study on three differ-
ent days.
2.5.4. Limit of detection and quantitation
In order to estimate the limit of detection (LOD) and limit of
quantitation (LOQ) linearly they were separately determined
based on the standard deviation (r) of the response and the
slope (S) of the calibration curve and using the formula
LOD= 3.3r/S and LOQ= 10r/S, the LOD and LOQ for
ACY were estimated.
2.5.5. Robustness
Robustness of the proposed method was studied by small but
deliberate variations in the optimized method parameters. Var-
iation in composition of the mobile phase (±0.1 mL), volume
of the mobile phase (±10%), chamber saturation timeTable 3 Statistical validation for accuracy study.
Level of recovery (%) % mean recoverya
ACY
80 99.97
100 99.95
120 100.02
a Mean of three determinations.(±20%), time from spotting to development (5 min, 20 min
and 40 mins) and time from development to scanning (5 min,
20 min and 40 min) was involved in this study. The effect ofStandard deviation % R.S.D. S.E.
ACY ACY ACY
±0.2523 1.2030 0.4821
±0.1692 1.2012 0.3123
±0.0721 1.2112 0.5155
Table 6 Results of analysis of Tab formulation.
Formulated
Tab
Average weight: 100mg
Sr. No. Weight of
Tab taken (mg)
Amount of
drug estimated
(mg/Tab taken) ACY
% label
claim ACY
1. 100 100.09 100.90
2. 100 99.98 99.91
3. 100 98.78 98.79
4. 100 99.04 99.06
5. 100 100.00 100.00
6. 100 101.10 101.13
Table 9 Results of degradation study
Sr. No. Stress condition Percent assay
of active
substance
(ACY)
Rf value
of degraded
product
1. Alkali (1 M NaOH) 98.65 0.41, 0.62, 0.87
2. Acid (1 M HCl) 99.83 0.61, 0.85
3. Oxidation(3% H2O2) 97.76 0.29, 0.45, 0.62, 0.87
4. Heat (60 C) 99.02 0.61, 0.72, 0.89
5. UV (240 nm) 99.19 0.62, 0.73
250 P.M. Patil et al.these changes on both the Rf values and peak areas was eval-
uated by calculating the relative standard deviation for each
parameter.
2.6. Stress studies
In order to evaluate the stability indicating property of the
developed HPTLC method stress studies were carried out
under ICH recommended conditions. Intentional degradation
was tried by exposing the tablet sample to the following stress
conditions: acid (0.1 N HCl at 60 C), base (0.1 N NaOH at
60 C), oxidation (3% H2O2 at 60 C), heat (60 C), and UV
light (254 nm). The ability of the proposed method to measure
the analyte response in the presence of its degradation prod-
ucts was studied.
2.7. Structure prediction of alkaline degradation of ACY
Into a series of 10 test tubes, 2.5 mL of ACY working solution
100 lg/mL was transferred and mixed with 2 mL of 1.0 M
sodium hydroxide. The test tubes were allowed to stand in a
thermostatically controlled oven at 100 C and then were
removed from the oven, one by one at 15 min time intervalTable 7 Statistical validation for analysis of Tab formulation.
Sr. No Drug Amount of drug estimated (mg/Tab)
1. ACY 99.83
a Mean of six determinations.
Table 8 Result of solution stability study.
Sr. No. Time Amount of drug estimated AC
1 20 9.98
2 1 h 9.78
3 2 h 9.04
4 4 h 10.00
5 12 h 10.10
6 24 h 9.98up to 180 min. The test tubes were immediately inserted into
an ice-bath to terminate the degradation reaction and then
were put in another water bath set at room temperature. The
contents of the test tubes were transferred into a 10.0 mL vol-
umetric ﬂask and diluted to required volume with methanol.
The proposed HPTLC method was applied for the determina-
tion of the remaining intact ACY at each time interval from its
corresponding regression equation. A plot of log of the
remaining concentration versus time in minutes was then
obtained to determine the alkaline degradation process as
depicted in Fig. 11. Structural elucidation of the obtained deg-
radation product was achieved by IR and Mass spectropho-
tometry and identiﬁed by Chromatogram of acyclovir and
degradant.
2.8. Band stability
To ascertain the stability of band, four bands of standard solu-
tion of ACY (100 lg/band) were applied on the TLC plate
using a Linomat 5 automatic sample applicator. The TLC
plate was then scanned at different time intervals viz. 20 mins,
1, 3, 8 and 24 h. The plate was stored in dark to exclude the
possible degradation effect of light. The peak start, peak apex,
peak area and peak purity of ACY peaks were recorded after
each time interval.% label claima S.D C.V. S.E
99.79 ±1.5128 ±1.6281 0.5181
Y % label claim S.D. (±) % C.V.
99.89 0.376 0.452
99.66 0.311 0.389
99.90 0.378 0.392
10.00 0.408 0.455
10.04 0.455 0.478
99.89 0.377 0.394
Figure 6 Chromatogram of 0.1 M HCl Tablet Formulation (1) ACY (2) degradant.
Figure 7 Chromatogram of 0.1 M NaOH Tablet Formulation (2) ACY (1, 3) degradant.
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3.1. Method optimization for the HPTLC-densitometric
measurements
During the development of HPTLC method several trials were
made by using mixture of different solvents containing non-
polar solvents and relatively polar solvents. Among the differ-
ent mobile phase combinations tested Toluene: n-butanol:
methanol: water (5.0:3.0:1.0:1.0 v/v/v) gave a better resolution
and sharp peaks with acceptable Rf values of 0.62 ± 0.05,
0.78 ± 0.05 for acyclovir and its alkaline degradation product,
respectively. A water mobile phase produces an environment
that should provide an inherent advantage of increased sig-
nal-to-noise ratio for detection in addition to saving on the
cost and expense of buying and disposing of toxic solventsand waste. The HPTLC densitogram of the mixture using
the optimum conditions is shown in Fig. 4.
3.2. Method validation
3.2.1. Linearity
A linear relationship was observed between peak area and con-
centration in the range of 100–600 ng/band for acyclovir. The
correlation coefﬁcient for the calibration curve was found to
be 0.9997. Each concentration level was analysed in a triplicate
fashion. The homoscedasticity of the calibration plot was eval-
uated with Cochran’s test. In order to achieve homoscedastic-
ity, the Cochran C of 4 standards with 3 replicates of each
standard should be less than the critical value of 0.768 as shown
in Table 1. Since the largest and smallest values of variance usu-
ally appear at the extremities of the calibration curve in the
Figure 8 Chromatogram of H2O2(3%) Tablet Formulation (3) ACY (1, 2 and 4) degradant.
Figure 9 Chromatogram of Dry Heat Tablet Formulation (1) ACY (2, 3 and 4) degradant.
252 P.M. Patil et al.heteroscedastic case, the two lowest concentrations (100 and
200 ng) and the two highest concentration (500 and 600 ng)
standards were included in the tests. The results are shown in
Fig. 5. The calibration curve passes the homoscedasticity test
as the C value is found to be less than the critical value.
3.2.2. Accuracy
The results of accuracy study are expressed in terms of percent
recovery. The percent recovery at three levels (80%, 100% and
120%) was found to be in the range of 98–102% (Tables 2 and 3)
indicating the accuracy of the proposed method.3.2.3. Precision
Repeatability and reproducibility of the proposed method
were ascertained by intra-day and inter-day precision studies.
The tablet formulation was assayed three times on the same
day (intra-day) and on three consecutive days (inter-day).
The results of precision studies were expressed in terms of rel-
ative standard deviation (RSD) of the percent label claim esti-
mated by the developed method (Table 4). The RSD for both
intra-day and inter-day precision study was found to be less
than 2 indicating the repeatability and reproducibility of the
method.
Figure 10 Chromatogram of UV Radiation Tablet Formulation (1) ACY (2) degradant.
Figure 11 Chromatogram of (1) acyclovir and (2) degradant in 1N NaOH for 12hrs.
Validated stability indicating HPTLC method for estimation of acyclovir in tablets 2533.2.4. Limit of detection and quantitation
The limits of detection and quantiﬁcation of the developed
method were calculated using 3a/S and 10a/S phenomena,
respectively. Where, a is the standard deviation of the y-inter-
cepts and S is the slope of the calibration curve. The limits of
detection and quantiﬁcation were found to be 8.08 and
12.16 ng/band, respectively as shown in Table 4.
3.2.5. Robustness
Robustness of the proposed method was studied by small but
deliberate variations in the optimized method parameters. The
effect of changes in the mobile phase composition (±0.1 ml),
amount of mobile phase (±1 ml), duration of chamber satura-
tion with mobile phase (±20%), time from spotting to devel-
opment (5, 20 and 40 min) and time from development to
scanning (5, 20 and 40 min) on Rf values and peak areas ofboth drugs was examined. The result of robustness study is
summarized in Table 5. The relative standard deviation for
peak area was found to be less than 2 under all the deliberately
varied method parameters. The resolutions between ACY and
degradant were not signiﬁcantly affected as there was no sig-
niﬁcant change in the Rf values of both the drugs (Rf values
were within 0.54 ± 0.05 Rf units of standard values). Hence,
the method was robust for the determination of ACY in ﬁxed
dose combination tablet.
3.3. Analysis of commercial tablet
The commercial tablet dosage form, Zovirax (200 mg) was
analysed using the developed HPTLC method. The analysis
was based on comparing the mean peak area of sample band
with that of the standard band. The results of tablet analysis
Figure 12 IR of Standard Acyclovir.
Figure 13 IR of Degradant (Acyclovir).
254 P.M. Patil et al.were in good agreement with the label claims (Table 6). The
results of the commercial dosage form analysis are presented
in Table 7.
3.3.1. Solution stability
Sample solution of ACY (100 lg/ml) was prepared and kept
at room temperature (25 ± 2 C) protected from day light.
The sample solution was assayed after 20 min, 1, 3, 8 and
24 h. Because of the time needed for sonication and ﬁltra-
tion, the fastest possible analysis was carried out within
20 min and hence results of the remaining analysis times
were compared with it. The percent label claim and the
RSD values are shown in Table 8. The results of solution
stability indicate that the solution is stable for 24 h. To
decrease systematic errors because of test solution instability,the analysis should be carried out within 24 h of sample
preparation.
3.4. Stress studies
In the forced degradation studies, ACY was found to degrade
under acidic, alkaline and oxidative stress conditions
employed. However it was found to be stable to the photo deg-
radation, thermal and neutral conditions employed. The
results of forced degradation studies are included in Table 9.
Typical densitograms obtained for ACY under different stress
conditions are shown in Figs. 6–10. The developed HPTLC
method could effectively resolve the drugs from their degrada-
tion products which conﬁrm the stability indicating power of
the developed method.
Figure 14 MS of Standard Acyclovir.
Table 10 Results of the effect of temperature and NaOH concentration on the rate of alkaline degradation of 100 lg/mL of ACY.
Temperature (C) Regression equation parameters (n= 6)a
Slope ± S.D. Intercept ± S.D. Correlation r2
40 0.048 ± 0.002 1.408 ± 0.258 0.9982
60 0.011 ± 0.008 1.410 ± 0.261 0.9911
80 0.182 ± 0.007 1.410 ± 0.331 0.9972
100 0.002 ± 0.005 1.408 ± 0.679 0.8653
NaOH concentration 0.5 M 0.503 ± 0.015 1.411 ± 0.711 0.9699
NaOH concentration 1 M 0.006 ± 0.002 1.404 ± 0.628 0.9973
a n, number of experiments.
Table 11 Results of band stability studies.
Concentration (lg/band) Time duration Peak start Peak apex Peak end Peak Area Peak purity %
100 20 min 0.55 0.61 0.65 6542.7 99.97
100 1 h 0.56 0.62 0.67 6543.8 100.00
100 3 h 0.57 0.63 0.67 6496.1 99.94
100 8 h 0.58 0.63 0.68 6352.2 92.14
100 24 h 0.58 0.62 0.65 5896.2 81.17
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ACY is smoothly hydrolysed with 1 M sodium hydroxide
after 2.5 h at 100 C, through the splitting of the ester group.
The expected major degradation product (DG) is obtained
according to the suggested mechanism for the alkaline degra-
dation process of Acyclovir, 15–18 (Fig. 11). The assignments
and structural elucidation of the degradation product were
conﬁrmed by the IR and mass spectral data. The IR spec-
trum (KBr) of DG was characterized by the absorption fre-
quency of NH2-band as a doublet at 3376.44 cm1, and
ACOO band at 1719 cm1, CAH at 3306 cm1 as shown inFig. 13 compared with ACY standard in Fig. 12. The mass
spectrum of DG was characterized by the appearance of
the molecular ion peaks at 194.07 m/z and 225.21 m/z (M
& M+ 2) which conﬁrm the molecular weight of the sug-
gested degradation product. Identiﬁed ACY and degradant
are depicted in Fig. 15 compared with ACY standard in
Fig. 14 and Table 10.
3.6. Band stability
The peak parameters recorded for ACY by scanning the TLC
plate at various time intervals up to 24 h (Table 11) did not
Figure 15 MS of Degradant (Acyclovir).
256 P.M. Patil et al.show any degradation. There was no signiﬁcant change in the
Rf values and peak purity of ACY was around 100% which
conﬁrmed that the bands applied on the TLC plate were stable
up to 24 h.
4. Conclusion
The developed HPTLC method was found to be simple, sensi-
tive, selective, and suitable for the determination of acyclovir
in the presence of its degradation products. Statistical analysis
proved that the method is repeatable, reproducible, accurate
and speciﬁc for the analysis of acyclovir. As the method is cost
effective and less time consuming, it may be more advantageous
for regulatory quality control laboratories especially to facilitate
the post-marketing surveillance programme. Thus, it can repre-
sent another good alternative for the already existing HPLC
methods. This research also reported good results in band stabil-
ity studied with their peak purity as shown in Table 11.
The assignments and structural elucidation of the degrada-
tion product were conﬁrmed by the IR and mass spectral data.
The IR spectrum (KBr) of DG was characterized by the
absorption frequency of NH2-band as a doublet at
3476.44 cm1 and AOH band at 3182.71 cm1, CAH at
3306 cm1. The mass spectrum of DG was characterized by
the appearance of the molecular ion peaks at 194.07 m/z and
225.21 m/z (M & M+ 2) which conﬁrm the molecular weight
of the suggested degradation product. Identiﬁed ACY and
degradant are depicted in Figs. 13 and 14.
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